To compare biologic disease-
Results: The sample comprised 9,782 biologic initiations; mean age 54 years and 82% female.
Compared with tocilizumab, the hazards of switching biologic therapy were significantly higher for abatacept [hazard ratio (HR) = 1.19, P = 0.041], adalimumab (HR = 1.39, P\0.001), certolizumab (HR = 1.39, P\0.001), golimumab (HR = 1.20, P = 0.047), and infliximab (HR = 1.33, P\0.001), but not significantly different for etanercept (HR = 1.19, P = 0.095); the hazards of switching/discontinuing biologic therapy were significantly higher for adalimumab (HR = 1.16, P = 0.014) and certolizumab (HR = 1.15, P\0.012), but not significantly different for abatacept (HR = 1.08, P = 0.229), etanercept (HR = 0.97, P = 0.644),
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INTRODUCTION
The 2010 European League Against Rheumatism (EULAR) and 2012 American College of Rheumatology (ACR) recommendations on rheumatoid arthritis (RA) management suggest switching to a different disease-modifying antirheumatic drug (DMARD) when biologictreated patients experience treatment failure, lack of efficacy, or toxicity [1, 2] . Accordingly, a switch between biologics may signal that the therapy from which a patient has switched was ultimately suboptimal for that patient; indeed, lack of efficacy and adverse events are among the most commonly documented reasons for switching biologic therapies [3] [4] [5] . Very little information has been published regarding biologic therapy persistence across biologic agents in the real-world setting and comparative information on biologic persistence for certolizumab, golimumab, and tocilizumab is unavailable. Furthermore, there is little information on biologic persistence among patients with RA who are not naïve to biologic treatment. Thus, the objective of this retrospective, observational cohort study was to compare biologic therapy persistence between biologics among patients with RA who have previously used at least one other biologic.
METHODS

Overview of Study Design
This was a retrospective, observational cohort study based on administrative claims data. The sample comprised patients with RA initiating biologic therapy after previously using at least one other biologic agent. Study outcomes were biologic persistence, defined in two alternative ways: (1) time from initiation until switching to a different biologic (time to switch) and (2) time from initiation until switching or the first occurrence of a 90-day gap in treatment with the initiated biologic (time to switch/ discontinuation). 
Data and Setting
Patient Selection Criteria
Patients included for study were patients with RA initiating a biologic treatment after previously using C1 other biologic. As described below, patients were classified as having RA on the basis of ICD-9-CM codes recorded on their medical claims and exposure to biologic therapy was identified on the basis of a prescription fill or visit to a physician during which an infusion was administered.
Specifically, patients were included in the analysis if they met all of the following 
Biologic Therapy Persistence Outcomes
The study outcomes were biologic therapy persistence, defined in two alternative ways:
(1) time from initiation until switching to a different biologic (time to switch) and (2) time from initiation until switching or the first occurrence of a 90-day gap in treatment with the initiated biologic. The follow-up of patients, who did not experience a switch, was censored at the end of the study period (March 31, 2012) or insurance disenrollment. As noted above, rituximab was excluded from the analyses. This is because courses of rituximab may be given every 24 weeks or based on clinical evaluation, we could not define a single time point from which a 90-day gap in therapy exposure would begin. Furthermore, because the re-treatment interval for rituximab is no sooner than 4 months after the prior infusion, it is possible that physicians would wait longer to switch patients from RTX, as compared with other biologics that have shorter re-treatment intervals. Thus, we conservatively chose to exclude rituximab from the analyses due to the uniqueness of re-treatment, which can complicate the measurement of persistence.
Rituximab use was still tracked, however, for the purpose of identifying cases in which patients switched to rituximab.
Covariates
The study covariates included patient demographics and clinical characteristics thought to potentially confound the relationship between the persistence outcomes and biologic agent. Patient demographics were measured at index and are listed in Table 1 .
Patient clinical characteristics were measured throughout the baseline period and are listed in Table 2 [8, 9] . Included in the list of clinical characteristics was an administrative claimsbased index for RA severity (CIRAS) score, which has been shown to have moderate correlations with a previously validated records-based index of severity that has established construct validity and convergent validity with the Disease Activity Score (DAS28) [10] . The CIRAS assigns a numerical value based on orders for inflammatory markers, number of platelet counts and chemistry panels ordered, rheumatoid factor, rehabilitation visits, age and gender, presence of Felty's syndrome and number of rheumatology visits. Details on the algorithm can be found in Ting et al. [10] . These covariates are consistent with prior research showing that demographic factors as well as measures of comorbidity, medication and other healthcare resource use to predict time to biologic discontinuation [11] .
Statistical Analysis
Bivariate analyses were used to display summary statistics for the variable distributions, stratified by biologic agent. The Kaplan-Meier (or productlimit) method was used to estimate the unadjusted probabilities of the persistence outcomes at 1 and 2 years after initiation [12] . Multivariable Cox proportional hazards models with the Huber-White ''sandwich'' variance estimator-which accounted for the possibility of multiple observations per patient-were used to compare the persistence outcomes between the biologic agents, adjusting for patient demographics and clinical characteristics listed in Tables 1 and 2 [13] [14] [15] . The variance inflation factor was used to assess multi-collinearity of the model's independent variables [16] . Plots of Schoenfeld residuals were used to assess whether the model's independent variables met the proportionality assumption of the Cox proportional hazards modeling approach [17] . In the multivariable analyses, tocilizumab was chosen as the reference category because for the time period during which this study was conducted, tocilizumab was the last entrant to the market and, among the more recently approved biologics including certolizumab and golimumab, had a unique (non-anti-TNF) mechanism of action. The choice of tocilizumab as the reference category therefore provided comparative information between it and each of Use of corticosteroids prior to initiation was common, with proportions ranging from 69.5% in golimumab-treated patients to 80.8% in tocilizumab-treated patients. Table 4 displays probabilities of biologic therapy persistence, as defined by time to switch/discontinuation, at 1 and 2 years after golimumab and infliximab, there is no difference between tocilizumab and these agents when we look at the time to switch/ discontinuation endpoint. These findings show that when we define discontinuation as a gap in therapy, the persistence for tocilizumab is similar to that of these three agents, implying that tocilizumab patients might have a longer gap in therapy before switching to a different agent. Because our data source did not contain detailed reasons as to why patients switch/ discontinue, we cannot conclude with certainty as to why this happens.
Biologic Therapy Persistence
Owing to the uniqueness of this investigation, there are very few studies to which these results can be compared. The majority of studies examining biologic therapy persistence rates among RA patients have focused largely on the first-line setting or have included only the anti-TNF agents such as adalimumab, etanercept, and infliximab [18] [19] [20] [21] [22] . One prior study by Ogale et al. [11] described switching between biologics among RA patients treated with abatacept, adalimumab, etanercept, infliximab, or rituximab in first-or subsequent-line settings. Ogale et al. [11] reported that in the subsequent-line setting, Among the covariates included in the multivariable models, there were several significant predictors of persistence. Predictors with consistent direction and significance across the two models included age (increase associated with better persistence), the Deyo-Charlson comorbidity index [increase (indicative of greater comorbidity) associated with better persistence], the number of non-biologic DMARDs in the baseline period (increase associated with better persistence), the number of unique three-digit ICD-9-CM diagnoses in baseline period (increase associated with slightly worse persistence), and the number of unique NDCs in the baseline period (increase associated with slightly worse persistence). With few exceptions, other covariates were generally consistent in direction across the models and statistically in significant. Although baseline use of corticosteroids was not statistically significantly associated with persistence, the high baseline use rates of corticosteroids were nevertheless notable, ranging from 69.5% in golimumab-treated patients to 80.8% in tocilizumab-treated patients. These rates were similar to the rates previously reported by Ogale et al. [11] , which among subsequent-line patients ranged from 69.9% in infliximab-treated patients to 74.9% in abatacept-treated patients. Low-dose corticosteroids therapy may be part of the treatment strategy in combination with DMARDs, though the appropriate duration of therapy is debated due to the adverse event profile of corticosteroids [1] . The study databases did not include information on patients' education or socioeconomic status, which may affect their access to, and ability to pay for, biologic treatments. This limitation is tempered by the fact that all patients included in the study were required to have initiated biologic therapy and had previously used at least one other biologic.
Therefore it is known that they have access to more than one biologic treatment.
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